slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 47,131-47,160
Pages 3,679
Rows per page 30
Component
47,131-47,160 of 110,355
178
The slide uses a historical stock chart to illustrate a previous crash as a warning for future performance.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
179
Uses SEC filing excerpts and a Notice of Effectiveness screenshot as evidence of insider dumping.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
180
The slide uses data from CapitalIQ to support a bearish thesis regarding insider selling.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
181
Uses historical precedent (Infinera) to cast doubt on current QS insiders; includes red dashed circles highlighting zero-balance positions.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
183
The slide uses red boxes and arrows to draw attention to specific, aggressive growth figures in the financial table.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
184
The slide uses expert testimony to debunk the company's timeline and valuation.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
185
QuantumScape (QS)QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
186
The slide uses direct quotes to undermine the credibility of the CEO's projections.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
187
Uses a quote from a VW employee to validate the argument.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
188
Uses a quote from a VW employee to undermine the company's timeline.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
04
The slide uses a direct user testimonial to highlight product safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
05
The slide presents anecdotal evidence of medical side effects to support an activist narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
06
The slide uses a social media post as a testimonial to highlight negative patient outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
07
The slide uses a screenshot of a Facebook post to undermine the clinical trial results of the drug VYKAT.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
11
The slide uses inflammatory language ('smelled a rat', 'drop like flies') to frame the company and investigator as negligent.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
12
Uses social media screenshots as primary evidence to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
13
Uses anecdotal evidence from Facebook groups to build a case for systemic safety issues.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
14
The slide uses a specific social media post as a case study to infer broader safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
15
Uses a screenshot of a Facebook group post as primary evidence to support the claim of medical danger.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
16
Uses direct quotes from Facebook posts to highlight patient safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
17
The slide highlights a discrepancy between the FDA label's explicit warnings about DKA and the company's omission of this risk in their phase 3 and open-label manuscripts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
18
The slide uses a Q&A format to build a case for the 'two-hit' hypothesis regarding drug interactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
19
The slide uses a combination of narrative description and citations of medical literature to establish the 'villain' (diazoxide) as dangerous.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
20
The slide uses direct excerpts from a medical paper to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
21
The slide uses a direct quote from the Pediatric Endocrine Society guidelines to expose the company's failure to address known side effects in their trial design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
22
The slide uses a direct quote from a medical paper to expose the ineffectiveness of the company's recommended treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
23
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the context of PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
24
The slide uses a combination of medical argumentation and cited conclusions to build a case against a specific treatment protocol.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
25
Uses emotional appeal and visual evidence to highlight the difficulty of diagnosing edema in PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
26
The slide uses anecdotal evidence from online discussion groups to highlight patient safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit